Itraconazol Heumann

Itraconazole, the active ingredient in Itraconazol Heumann, is a triazole antifungal presented as an oral formulation for systemic use. It is employed to treat a range of serious fungal infections, including systemic candidiasis, invasive aspergillosis, onychomycosis and dermatophyte skin infections, primarily in adult patients.

GNH USA supplies Itraconazol Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Itraconazole is indicated for several invasive and superficial fungal infections, targeting organisms that rely on ergosterol synthesis. - Dermatophyte infections: treats skin and nail infections caused by dermatophyte fungi, improving lesion clearance. - Onychomycosis: eradicates fungal infection of the nail plate, promoting regrowth of healthy nail. - Systemic candidiasis: combats invasive Candida species in bloodstream and internal organs, reducing mortality risk. - Invasive aspergillosis: effective against Aspergillus species in immunocompromised patients, aiding disease control.

Itraconazole may cause a range of adverse reactions, varying from mild to severe, that should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often transient. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: dull or throbbing pain, usually self‑limiting. - Rash: skin redness or itching without systemic involvement. - Elevated liver enzymes: mild, reversible increase in hepatic markers.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice, or hepatitis. - Congestive heart failure: worsening of cardiac function, especially in patients with pre‑existing disease. - Severe liver injury: hepatic failure requiring medical intervention. - Arrhythmias: abnormal heart rhythms, including QT prolongation. - Visual disturbances: blurred vision or photopsia. - Anaphylaxis: rare, life‑threatening allergic reaction.

When prescribing itraconazole, clinicians should observe several precautionary measures to minimize risk and ensure safe use. - Monitor liver function: obtain baseline hepatic enzymes and repeat periodically during treatment. - Assess cardiac status: avoid use in patients with existing heart failure or significant ventricular dysfunction. - Review concomitant medications: identify drugs that may interact via CYP3A4 metabolism. - Evaluate hypersensitivity: discontinue if signs of allergic reaction such as rash or angioedema appear. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at ambient temperature: keep in original container, protect from moisture and light.

Itraconazole is metabolized by and can affect the activity of several cytochrome P450 enzymes, leading to important drug‑drug interactions.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that markedly reduces itraconazole plasma concentrations. - Ketoconazole: additive hepatotoxic potential when combined with itraconazole. - St. John’s wort: herbal inducer that decreases itraconazole exposure and efficacy.

Moderate Interactions (Monitor Closely): - Erythromycin or clarithromycin: CYP3A4 inhibitors that can increase itraconazole levels, requiring dose adjustment. - Statins (e.g., simvastatin): increased risk of myopathy due to higher statin concentrations. - Antacids, H2‑blockers, or proton pump inhibitors: may reduce oral absorption of itraconazole, consider timing separation.